SeqVision - Company finances
|
EUR
|
2022
From: 2022-02-03
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|
|
Financial data
|
||||
| Sales revenue | 6,717 | 28,201 | 101,990 | 128,899 |
| Profit before tax | -205 | 20,257 | 36,855 | -810 |
| Net profit | -205 | 19,252 | 34,982 | -810 |
| Equity | 95 | 19,347 | 55,029 | 54,219 |
| Liabilities | 6,563 | 3,284 | 15,353 | 30,713 |
| Non-current assets | 0 | 1,819 | 5,437 | 4,078 |
| Current assets | 6,658 | 20,812 | 64,945 | 80,854 |
| Total assets | 6,658 | 22,631 | 70,382 | 84,932 |
|
Taxes paid
|
||||
| STI taxes | - | 32 | 8,807 | 23,681 |
| Social insurance contributions | - | - | - | 6,349 |
|
Financial indicators
|
||||
| Revenue change y/y | - | +319.8% | +261.7% | +26.4% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -3.1% | 85.1% | 49.7% | -1.0% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -215.8% | 99.5% | 63.6% | -1.5% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -3.1% | 68.3% | 34.3% | -0.6% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -3.1% | 71.8% | 36.1% | -0.6% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 69.1 | 0.2 | 0.3 | 0.6 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | 33,997 | 36,828 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
SeqVision - Social security debts
The company had no debts to Sodra
SeqVision - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-06-28 | 2025-07-24 | 0.48 |
| 2025-06-19 | 2025-06-24 | 0.48 |
| 2024-10-02 | 2024-10-16 | 0.01 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
SeqVision, UAB (code 306001603) is a private limited liability company engaged in research and experimental development on other natural sciences and engineering. In 2025, revenue increased to €128.9K, up 26.4% year on year and 357.1% compared with 2023, when revenue was €28.2K. Profitability softened after a strong 2024: net profit reached €19.3K in 2023 and €35.0K in 2024, but the company posted a small net loss of €810 in 2025, resulting in a -0.6% profit margin. The balance sheet continued to expand, with total assets rising to €84.9K in 2025 from €22.6K in 2023. Equity stood at €54.2K and liabilities at €30.7K at year-end 2025. Key ratios remained solid despite the loss, including an equity ratio of 63.8%, debt-to-equity of 0.57 and asset turnover of 1.52x. ROE was -1.5% and ROA -0.9% in 2025. Revenue per employee was €43.0K, while profit per employee was -€270.